Davis R M Inc. reduced its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 41.0% during the second quarter, Holdings Channel reports. The institutional investor owned 103,315 shares of the medical instruments supplier’s stock after selling 71,755 shares during the period. C.R. Bard comprises about 1.4% of Davis R M Inc.’s holdings, making the stock its 29th largest position. Davis R M Inc.’s holdings in C.R. Bard were worth $32,659,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in BCR. Cribstone Capital Management LLC bought a new stake in shares of C.R. Bard during the first quarter valued at approximately $130,000. Contravisory Investment Management Inc. raised its stake in shares of C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 426 shares in the last quarter. Whittier Trust Co. raised its stake in shares of C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 42 shares in the last quarter. ClariVest Asset Management LLC bought a new stake in shares of C.R. Bard during the first quarter valued at approximately $148,000. Finally, SRS Capital Advisors Inc. raised its stake in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares in the last quarter. 85.32% of the stock is currently owned by institutional investors and hedge funds.

C.R. Bard, Inc. (NYSE:BCR) opened at 318.58 on Monday. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27. The firm has a 50-day moving average price of $317.93 and a 200 day moving average price of $279.50. The company has a market cap of $23.15 billion, a P/E ratio of 41.82 and a beta of 0.59.

C.R. Bard (NYSE:BCR) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.84 by $0.08. The firm had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.54 EPS. On average, equities analysts expect that C.R. Bard, Inc. will post $11.79 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, August 4th. Shareholders of record on Monday, July 24th were issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio is presently 13.67%.

WARNING: “C.R. Bard, Inc. (BCR) Position Cut by Davis R M Inc.” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/07/c-r-bard-inc-bcr-position-cut-by-davis-r-m-inc.html.

BCR has been the topic of several recent analyst reports. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price target on the stock in a research note on Tuesday, June 6th. BMO Capital Markets reaffirmed a “buy” rating and issued a $255.00 price target on shares of C.R. Bard in a research note on Tuesday, April 11th. BidaskClub lowered C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Morgan Stanley lowered C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. Finally, Jefferies Group LLC boosted their price target on C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a research note on Monday, April 24th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $285.67.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.